Single-cell imaging of CAR T cell activity in vivo reveals extensive functional and anatomical heterogeneity
Cheadle, Eleanor J
AffiliationDynamics of Immune Responses Unit, Equipe Labellisee Ligue Contre le Cancer, Institut Pasteur, INSERM U1223, Paris, France
MetadataShow full item record
AbstractCAR T cells represent a potentially curative strategy for B cell malignancies. However, the outcome and dynamics of CAR T cell interactions in distinct anatomical sites are poorly understood. Using intravital imaging, we tracked interactions established by anti-CD19 CAR T cells in B cell lymphoma-bearing mice. Circulating targets trapped CAR T cells in the lungs, reducing their access to lymphoid organs. In the bone marrow, tumor apoptosis was largely due to CAR T cells that engaged, killed, and detached from their targets within 25 min. Notably, not all CAR T cell contacts elicited calcium signaling or killing while interacting with tumors, uncovering extensive functional heterogeneity. Mathematical modeling revealed that direct killing was sufficient for tumor regression. Finally, antigen-loss variants emerged in the bone marrow, but not in lymph nodes, where CAR T cell cytotoxic activity was reduced. Our results identify a previously unappreciated level of diversity in the outcomes of CAR T cell interactions in vivo, with important clinical implications.
CitationCazaux M, Grandjean CL, Lemaitre F, Garcia Z, Beck RJ, Milo I, et al. Single-cell imaging of CAR T cell activity in vivo reveals extensive functional and anatomical heterogeneity. J Exp Med. 2019 Apr 1.
JournalThe Journal of Experimental Medicine
- Long-term in vivo microscopy of CAR T cell dynamics during eradication of CNS lymphoma in mice.
- Authors: Mulazzani M, Fräßle SP, von Mücke-Heim I, Langer S, Zhou X, Ishikawa-Ankerhold H, Leube J, Zhang W, Dötsch S, Svec M, Rudelius M, Dreyling M, von Bergwelt-Baildon M, Straube A, Buchholz VR, Busch DH, von Baumgarten L
- Issue date: 2019 Nov 26
- A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells.
- Authors: Kueberuwa G, Zheng W, Kalaitsidou M, Gilham DE, Hawkins RE
- Issue date: 2018 Oct 16
- Anti-CD37 chimeric antigen receptor T cells are active against B- and T-cell lymphomas.
- Authors: Scarfò I, Ormhøj M, Frigault MJ, Castano AP, Lorrey S, Bouffard AA, van Scoyk A, Rodig SJ, Shay AJ, Aster JC, Preffer FI, Weinstock DM, Maus MV
- Issue date: 2018 Oct 4
- Construction of a new anti-CD19 chimeric antigen receptor and the anti-leukemia function study of the transduced T cells.
- Authors: An N, Tao Z, Li S, Xing H, Tang K, Tian Z, Rao Q, Wang M, Wang J
- Issue date: 2016 Mar 1
- Chimeric Antigen Receptor T-Cell Therapies for Aggressive B-Cell Lymphomas: Current and Future State of the Art.
- Authors: Abramson JS, Lunning M, Palomba ML
- Issue date: 2019 Jan